@MarkC53916729 @DewDiligence A well-designed HBV drug using RNAi as a backbone $JNJ + $ARWR might never need to use pegIFN because results might show endogenous-IFNs (maybe Type-I IFN) being produced at a more natural, non-systemic level than in combo with pegIFN as a drug. $VIR results might not be as good.